ClinicalTrials.gg
RecruitingNCT07505342REACH-DMUpdated Apr 1, 2026

Remote Assessments and Genetic Determinants of Myotonic Dystrophy

An observational study in Myotonic Dystrophy Type 1 (DM1) and DM1, sponsored by University of Rochester. Recruiting at 1 site in United States. Open to participants aged 18 Years to 88 Years. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by University of Rochester · Observational

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years to 88 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.

Planned enrollment
4th of 21
1,000 · median 125
Started
2022
with 5 others
Observational
21 of 43
15 open now
Primary completion
2030-01
later than 18 of 26 live
Registered
38th of 43
by date
Lead sponsor
6 of 43
University of Rochester

Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 4th largest by planned enrollment of the 21 observational ones that give a count, is one of 6 that started in 2022, is one of 21 observational ones, reaches primary completion later than 18 of the 26 other live ones, and was the 38th registered.

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 88 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Myotonic Dystrophy with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study, conducted in participants' homes and requiring no travel to a study site, is to better understand disease variability in people with myotonic dystrophy type 1 (DM1) and to identify effective ways to measure symptoms.

Myotonic dystrophy is one of the most variable diseases. Some people develop symptoms when they are young, others when they are much older. In the same family, some people may have mild problems, while others are strongly affected. The goal of this study is to find out more about what is causing these differences. To accomplish this, investigators will study the effects of DM1 on skeletal and smooth muscles, the heart, and the nervous system. Then, investigators will evaluate genetic differences with a blood sample.

  • Participants will receive a toolkit in the mail which includes all necessary equipment to participate in the study, including an iPad with video conferencing software.
  • Then the study team will connect with participants via videoconferencing for medical interview about DM1 symptoms and functional assessments
  • Participants will have their blood drawn in a lab in their community or using a home draw device, and ship it to us for research genetic analysis
  • Participants can chose to have their research genetic test result returned to them
03

Conditions studied

  • Myotonic Dystrophy Type 1 (DM1)
  • DM1

Browse trials for

04

Who can participate

Ages eligible
18 Years to 88 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Myotonic dystrophy DM1 between the ages of 18-88 years old

Eligibility criteria

Inclusion Criteria:

  • Age 18-88 years
  • Clinical diagnosis of DM1
  • English speaking
  • Able to provide
  • Available wifi
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Remote assessment of grip strength

    Grip strength will be assessed using a hand held dynamometer (strength measured in kg)

    Time frame: 12 months

  2. Remote assessment of cognitive function

    Participants will complete a memory tests on the study iPad lasting less than 10 minutes. Scoring will look at the number of correct answers as well as time to complete (in seconds).

    Time frame: 12 months

  3. Remote assessment of activity

    Participants will wear an activity monitor for 7 days. One device is worn on the wrist like a watch and the other on the waistband of participants pants

    Time frame: 12 months

  4. Genetic test

    Participants will have their blood drawn in a lab in their community and ship it to us using a pre-paid shipping label. If not able, a home blood draw kit will be provided. DNA will be extracted from the blood and the CTG repeat length will be determined. If a participant chooses to, they will receive a letter with their research genetic test result.

    Time frame: at baseline

  5. Timed Up and Go

    Participant will sit in a chair, stand up, walk a designated distance, turn around and return to the chair to sit down. The amount of time it takes to complete this will be documented in seconds

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Aggregated and deidentified data will be shared with qualified investigators.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Jan 2030, 91 months after the start.

Of 36 observational studies under Myotonic Dystrophy, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35. This study's planned 91 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Apr 1, 2026
StartActual
May 10, 2022
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jan 1, 2030
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07505342
Collaborators
Muscular Dystrophy Association, Myotonic Dystrophy Foundation (MDF), National Institutes of Health (NIH)
Responsible party
Johanna Hamel (Associate Professor of Neurology, Pathology and Laboratory Medicine, University of Rochester) — Principal investigator
First posted
Apr 1, 2026
Start date
May 10, 2022
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Apr 1, 2026

Study contacts

Jeanne Dekdebrun
Contact
REACHDM@URMC.rochester.edu
585-275-0420
Johanna Hamel, MD
principal investigator · University of Rochester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion